medications

What is Survodutide and how does it compare?

Survodutide is an experimental dual GLP-1/glucagon receptor agonist developed by Zealand Pharma and Boehringer Ingelberg currently in phase 3 trials. Unlike tirzepatide (GLP-1/GIP), survodutide combines GLP-1 appetite suppression with glucagon's effects on energy expenditure and hepatic glucose metabolism. Phase 2 data showed up to 18.7% weight loss at the highest dose. The glucagon component may provide additional benefits for fatty liver disease and metabolic rate. If approved, it would represent another dual-mechanism option alongside tirzepatide, with potentially different side effect profiles and efficacy patterns. Results from the SYNCHRONIZE phase 3 program are expected in 2025-2026.

survodutideexperimentaldual agonistglucagon

Need provider-specific guidance?

Visit GLP1Search.com to learn about emerging medications

Compare Providers

Related questions

What is the difference between Ozempic and Wegovy? What is the difference between Mounjaro and Zepbound? How does semaglutide compare to tirzepatide for weight loss? What is Retatrutide and how is it different? What is the difference between daily and weekly GLP-1 injections?